On December 24, Gelonghui reported that Tibet Aim Pharm. Inc. (002826.SZ) announced that the third-party cooperative product, Gua Lou Pi Injection (Xintong), is a variety operated in cooperation with a subsidiary of SH PHARMA. Currently, after sufficient consultation with SH PHARMA, the company has decided to terminate the cooperation, and the agreement will not be renewed after December 2024. According to preliminary calculations by the finance department, the revenue generated by this product in 2024 is expected to be 85 million yuan, accounting for over 10% of the company's most recent audited revenue. In accordance with the Shenzhen Stock Exchange's Stock Listing Rules and relevant regulations, this matter meets the disclosure standards.
The termination of the product cooperation is based on changes in the market environment and the company's strategic planning adjustment, concentrating resources on developing self-produced products to maintain the performance growth of self-produced products. This decision is the result of careful study and mutual agreement between both parties and will not have a significant impact on the company's financial and operational status, nor will it harm the rights and interests of the company and minority shareholders, and it does not affect the company's future development plans. The company will further focus on self-produced products, promote sustainable and healthy development, and enhance the company's overall competitiveness.
